— Know what they know.
Not Investment Advice

NDTP OTC

NDT Pharmaceuticals Inc.
1W: -35.9% 1M: -39.2% 3M: -44.5% YTD: -84.0% 1Y: -78.2% 3Y: -94.8% 5Y: +121328.6%
$0.26
+0.01 (+2.00%)
 
Weekly Expected Move ±23.8%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Strong Sell · Power 36 · $40.8M mcap · 56M float · 0.0046% daily turnover · Short 41% of daily vol

Balance Sheet Trends

Total Assets
$143K +0.0% ▲
5Y CAGR: -15.4%
Total Liabilities
$42K +0.0% ▲
5Y CAGR: -36.4%
Shareholders Equity
$101K +0.0% ▲
Cash & Investments
$647 +0.0% ▲
5Y CAGR: -39.2%
Total Debt
$0 +0.0% ▲
Net Debt
-$647 +0.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2014FY2015FY2016FY2017FY2023
— Assets —
Cash$89K$2K$67$0$647
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$89K$2K$67$0$647
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$0$0$0
Total Current Assets$89K$2K$67$0$647
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$50K$50K$50K$50K$0
Long-Term Investments$0$0$0$0$142K
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$50K$50K$50K$50K$142K
Total Assets$139K$52K$50K$50K$143K
— Liabilities —
Accounts Payable$0$0$0$0$0
Short-Term Debt$350K$350K$350K$350K$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$5K$7K$8K$9K$42K
Total Current Liabilities$355K$357K$358K$359K$42K
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$0$0$0$0
Total Liabilities$355K$357K$358K$359K$42K
— Equity —
Common Stock$302$302$302$302$16K
Retained Earnings-$216K-$305K-$308K-$309K-$107K
Accumulated OCI-$302-$302-$302-$302$0
Total Stockholders Equity-$216K-$305K-$308K-$309K$101K
Total Liabilities & Equity$139K$52K$50K$50K$143K
— Key Metrics —
Total Debt$350K$350K$350K$350K$0
Net Debt$261K$348K$350K$350K-$647
Total Investments$0$0$0$0$142K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms